IHH Healthcare said on Thursday its unit has sought up to 109.3 billion rupees ($1.25 billion) in compensation from Japan's ...

Northern TK Venture Pte Ltd, IHH Healthcare's Singaporean arm, has raised its claim against Daiichi Sankyo in Tokyo for ...

AN INDIRECT, wholly owned subsidiary of integrated healthcare player IHH Healthcare, Northern TK Venture (NTK), on Thursday (Feb 6) submitted an additional brief to the Tokyo District Court, including ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao Manabe, DVM, PhD, will continue to serve as representative director and ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

IHH Healthcare Bhd’s unit is seeking compensation ranging from 4.24 billion rupees (RM200mil) to 109.3 billion rupees (RM5.7bil) from Japan's Daiichi Sankyo for its stake purchase in India's Fortis ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...

The company had initially claimed 20 billion yen ($130.99 million) that Daiichi was ordered to pay as damages to NTK in ...